Skip to main content

Table 1 Parameters at baseline and at the 8 weeks follow-up

From: Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

  Control Diabetes Diabetes+dapa
Baseline
 Body weight, kg 3.3 ± 0.1 3.3 ± 0.1 3.4 ± 0.1
 Total cholesterol (mg/dL) 29.8 ± 3.1 32.3 ± 4.1 27.9 ± 2.5
 Triglyceride (mg/dL) 42.3 ± 5.9 38.2 ± 4.6 36.9 ± 5.9
 High-density lipoprotein (mg/dL) 13.9 ± 2.2 14.8 ± 2.5 12.9 ± 1.9
 Low-density lipoprotein (mg/dL) 7.4 ± 1.5 9.9 ± 3.0 7.6 ± 1.1
 FBG (mg/dL) 133 ± 8 427 ± 36*** 441 ± 38***
At 8 week follow-up
 Body weight, kg 3.6 ± 0.1 3.5 ± 0.2 3.8 ± 0.1
 Total cholesterol (mg/dL) 268 ± 42 645 ± 34*** 266 ± 27†††
 Triglyceride (mg/dL) 91.4 ± 32.6 669 ± 161*** 138 ± 35††
 High-density lipoprotein (mg/dL) 40.6 ± 2.5 26.1 ± 2.4*** 25.7 ± 2.9***
 Low-density lipoprotein (mg/dL) 209 ± 36 486 ± 34*** 213 ± 21†††
 FBG (mg/dL) 136 ± 4 445 ± 48*** 251 ± 36*,†
  1. Values are means ± SEM (n = 10 per group)
  2. FBG fasting blood glucose
  3. *p < 0.05, ***p < 0.001 compared to control group, p < 0.05, ††p < 0.01, †††p < 0.001 compared to diabetes group